{"id":295319,"date":"2023-06-01T00:00:00","date_gmt":"2023-06-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreop0007-2023-biopharma-dry-eye-access-reimbursement-access-reimbursement-dry-eye-disease-us\/"},"modified":"2026-03-31T10:33:06","modified_gmt":"2026-03-31T10:33:06","slug":"acreop0007-2023-biopharma-dry-eye-access-reimbursement-access-reimbursement-dry-eye-disease-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreop0007-2023-biopharma-dry-eye-access-reimbursement-access-reimbursement-dry-eye-disease-us\/","title":{"rendered":"Dry Eye &#8211; Access &#038; Reimbursement &#8211; Access &#038; Reimbursement &#8211; Dry Eye Disease (US)"},"content":{"rendered":"<p>For more than a decade, AbbVie\u2019s Restasis was the only <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved therapy for dry eye disease (<abbr title=\"dry eye disease\">DED<\/abbr>) until the launch of Novartis\u2019s Xiidra in 2016, followed by Restasis MultiDose, Sun Ophthalmics\u2019 Cequa, Alcon\u2019s Eysuvis, and, more recently, Oyster Point\u2019s Tyrvaya. In addition to these drugs, off-label ophthalmic corticosteroids and antibiotics are often prescribed for <abbr title=\"dry eye disease\">DED<\/abbr>. Competition has further increased with the launch of the first generics of Restasis in February 2022 and will continue to increase with the expected near-term launch of other late-stage agents, particularly Aldeyra\u2019s ADX-102 and Novaliq\u2019s CyclASol. Because treatment burden plays a critical role in the management of <abbr title=\"dry eye disease\">DED<\/abbr>, it is important to understand the preferences and expectations of physicians and payers regarding approved and emerging therapies. This report explores drivers of physicians\u2019 and payers\u2019 prescribing and coverage decisions and their receptivity to emerging agents for <abbr title=\"dry eye disease\">DED<\/abbr>. These preferences dictate prescribing trends and patient access to <abbr title=\"dry eye disease\">DED<\/abbr> therapies, ultimately shaping the future treatment landscape and market dynamics.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Does coverage of key <abbr title=\"dry eye disease\">DED<\/abbr> brands differ on <abbr title=\"managed care organization\">MCO<\/abbr>s\u2019 largest Medicare Part D and commercial insurance plans?<\/li>\n<li>What are the current prescribing practices for <abbr title=\"dry eye disease\">DED<\/abbr>, and how are they impacted by payer policy?<\/li>\n<li>How receptive are payers to drugs in late-stage development for <abbr title=\"dry eye disease\">DED<\/abbr>? What coverage decisions do they anticipate? How do ophthalmologists and optometrists expect to prescribe the agents?<\/li>\n<li>How do payers\u2019 utilization management strategies impact physicians\u2019 prescribing of approved <abbr title=\"dry eye disease\">DED<\/abbr> therapies, and how is generic Restasis, launched in the United States in February 2022, prescribed and reimbursed for <abbr title=\"dry eye disease\">DED<\/abbr>?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS <\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong> Survey of 100 U.S. ophthalmologists and optometrists, survey of 30 U.S. <abbr title=\"managed care organization\">MCO <\/abbr><abbr title=\"pharmacy director\">PD<\/abbr>s \/ <abbr title=\"medical director\">MD<\/abbr>s<\/p>\n<p><strong>Fingertip formulary: <\/strong>Formulary coverage and restrictions data for <abbr title=\"dry eye disease\">DED<\/abbr> therapies by commercial plans covering approximately 163.6 million lives and Medicare Part D plans covering 36.7 million lives nationally.<\/p>\n<p><strong>Key drugs covered:<\/strong><strong> <\/strong> Restasis, Restasis MultiDose, Xiidra, Cequa, Klarity-C, Eysuvis, Tyrvaya, CyclASol, NOV03, RGN-259, ADX-102<\/p>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Reimbursement and contracting.<\/p>\n<p>Access and prescribing.<\/p>\n<p>Opportunities and challenges for emerging therapies.<\/p>\n<p>Disease-specific special topic.<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement <\/em>provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-295319","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-dry-eye","biopharma-therapy-areas-ophthalmology","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295319\/revisions"}],"predecessor-version":[{"id":576099,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295319\/revisions\/576099"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}